Drug Search Results
More Filters [+]

Revusiran

Alternative Names: revusiran
Latest Update: 2021-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TTR Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alnylam
Company Location: CAMBRIDGE MA 02142
Company CEO: Yvonne L. Greenstreet
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Revusiran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Amyloidosis, Familial|Amyloid Neuropathies, Familial|Cardiomyopathies|Transthyretin Amyloidosis

Phase 2: Amyloidosis|Transthyretin Amyloidosis|Amyloidosis, Familial|Polyneuropathies|Amyloid Neuropathies, Familial

Phase 1: Amyloidosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-003835-20

P3

Completed

Transthyretin Amyloidosis

2017-03-30

ENDEAVOUR

P3

Completed

Transthyretin Amyloidosis|Cardiomyopathies|Amyloidosis, Familial|Amyloid Neuropathies, Familial

2017-03-30

2014-001229-34

P2

Completed

Transthyretin Amyloidosis

2017-02-22

ALN-TTRSC-003

P2

Completed

Amyloidosis

2017-02-22

Recent News Events